Bernd R. Seizinger Buys 10,000 Shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) Stock

Aprea Therapeutics, Inc. (NASDAQ:APRE) Director Bernd R. Seizinger acquired 10,000 shares of the company’s stock in a transaction that occurred on Friday, October 11th. The stock was purchased at an average price of $2.68 per share, for a total transaction of $26,800.00. Following the acquisition, the director now directly owns 44,730 shares of the company’s stock, valued at $119,876.40. The trade was a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Aprea Therapeutics Stock Performance

NASDAQ:APRE opened at $3.50 on Thursday. The stock’s 50 day moving average price is $3.16 and its 200 day moving average price is $4.19. Aprea Therapeutics, Inc. has a 52 week low of $2.15 and a 52 week high of $8.85. The company has a market capitalization of $19.01 million, a P/E ratio of -1.05 and a beta of 1.03.

Aprea Therapeutics (NASDAQ:APRE) last announced its earnings results on Monday, August 12th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.05. The firm had revenue of $0.56 million during the quarter, compared to analysts’ expectations of $0.10 million. Aprea Therapeutics had a negative return on equity of 56.38% and a negative net margin of 1,012.37%. As a group, sell-side analysts forecast that Aprea Therapeutics, Inc. will post -2.74 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Wedbush restated an “outperform” rating and issued a $11.00 price objective on shares of Aprea Therapeutics in a report on Tuesday, August 13th. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Aprea Therapeutics in a report on Monday, August 12th.

Institutional Investors Weigh In On Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. Stonepine Capital Management LLC bought a new position in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 137,174 shares of the company’s stock, valued at approximately $558,000. Aprea Therapeutics accounts for 0.5% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 21st biggest position. Stonepine Capital Management LLC owned about 2.53% of Aprea Therapeutics at the end of the most recent quarter. 34.19% of the stock is owned by hedge funds and other institutional investors.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.